Quick Answer
Neuphoria Therapeutics Inc. reported Net Income of -$369.6 thousand for fiscal year 2025.
Neuphoria Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$369.6K | +97.6% |
| 2024 | -$15.49M | +27.5% |
| 2023 | -$21.38M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.86M | +195.9% | +118.8% |
| September 30, 2025 | -$9.91M | -1130.9% | -188.0% |
| March 31, 2025 | $11.26M | +505.4% | +679.5% |
| December 31, 2024 | -$1.94M | +57.3% | -141.5% |
| September 30, 2024 | -$804.8K | +85.3% | +71.0% |
| March 31, 2024 | -$2.78M | — | +39.0% |
| December 31, 2023 | -$4.55M | — | +16.8% |
| September 30, 2023 | -$5.47M | — | — |
- Neuphoria Therapeutics Inc. showed an increase of +97.6% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Neuphoria Therapeutics Inc.’s net income has grown by 98.3% (from -$21.38 million to -$369.6 thousand).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: